Aakaar Medical Technologies Q2 FY27 Share Price & Earnings Call Analysis

₹74.20+2.26% today
Market cap
₹105 Cr
P/E
9.59
ROE
17.07%
PEG
0.21
Price to sales
1.23
Debt to equity
0.33
52W high / low
₹84.0 / ₹48.0
Sales growth (5Y)
40.02%
EBITDA margin
18.57%
Net profit margin
9.92%
Promoter holding
67.05%
Sales (last year)
₹85 Cr

Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices.[1]

Guidance scorecard · Q2 FY27 call

What Aakaar Medical's management guided
and where it ranks in Personal Products

#4of 8 in
Personal Products

RevenueQ2 FY27 call

20–40%
  • Aakaar Medical Technologies targets a CAGR of around 36% in revenue growth going forward, with optimism of reaching 50% CAGR in the coming years.
  • The company aims to regain lost momentum from prior years and sustain profitable year-on-year growth.
  • Expansion plans include increasing distribution network from 40 to 100 distributors over two years to improve last-mile delivery and collections.
  • Growth is expected from enhanced sales of both imported and Aakaar's own brands, with the latter projected to constitute about 36-37% of revenue by year-end.
  • New initiatives like FotoFinder device sales and the Xelix franchise model are expected to add to revenue.
  • Aakaar plans to launch a direct-to-consumer website to capture revenue leakage and boost brand sales and margins.

2 more points from Aakaar Medical's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Aakaar Medical said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Aakaar Medical Technologies has already allocated funds for R&D over multiple periods for product development, including the Xelix hair transplant device.
  • The Xelix hair transplant device is nearing completion with the prototype finalized and nearing the test license filing stage with CDSCO.
  • No significant new capex or large-scale manufacturing investments currently planned; focus remains on sales and marketing.
  • Own manufacturing is considered only if there is a unique product proposition requiring proprietary control, otherwise third-party or loan license manufacturing is preferred.

2 more points from Aakaar Medical's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Aakaar Medical said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • The company has seen strong revenue growth, with H1 FY27 revenue at INR 43.72 crores, up 72.64% YoY.
  • They are confident of maintaining a CAGR of around 36% going forward.
  • Several deals in pipeline related to FotoFinder devices could contribute to achieving annual targets.
  • The Xelix clinic network has onboarded 70+ doctors; targeting 100 doctors soon before scaling marketing and lead generation.

2 more points from Aakaar Medical's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Personal Products
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Personal Products companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹1,858 Cr55.5
240%+Flat₹408 Cr36.4
3Honasa Consumer Ltd20–40%Up 0–2%₹14,422 Cr57.1
4Aakaar MedicalThis stock20–40%Flat₹101 Cr9.2
510–20%Flat₹86,892 Cr40.9
610–20%Flat₹64,856 Cr32.7

Sign up free to see every company in the sector ranking and track Aakaar Medical.

Pro shows every company guiding 40%+ revenue growth →Full Personal Products ranking

Financials of Aakaar Medical

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Aakaar Medical

Shareholding breakup across reporting periods.

Jun 2025Sep 2025Mar 2026Sep 2026
Promoters +67.01%67.01%67.05%67.05%
FIIs +1.87%0.50%0.00%0.00%
DIIs +12.33%10.73%11.17%10.13%
Public +18.79%21.77%21.78%22.82%
No. of Shareholders920603550558

Financials of Aakaar Medical

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Aakaar Medical

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +2312193346626785
Sales growth-46%+57%+68%+41%+34%+9%+44%
Expenses +2012172941525770
Operating Profit31245101016
OPM %13%7%12%11%11%16%15%19%
Other Income +00000011
Interest00001222
Depreciation00000000
Profit before tax212348915
Tax %27%29%26%31%26%26%28%
Net Profit +212236711
EPS in Rs2.010.591.782.363.155.794.697.74
Dividend Payout %0%0%35%24%0%0%0%

Financials of Aakaar Medical

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital0.100.100.700.700.70101414
Reserves777912134044
Borrowings +644615231919
Other Liabilities +436868612
Total Liabilities1614182334547988
Fixed Assets +00000001
CWIP00000000
Investments00000000
Other Assets +1614182334547987
Total Assets1614182334547988

Financials of Aakaar Medical

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-040-3-8-5-8
Cash from Investing Activity +00-0-0-0-00
Cash from Financing Activity +0-2-1181119
Net Cash Flow03-1-20510
Free Cash Flow-040-3-8-5-9
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit10%503%47%-54%-136%-35%-59%

Financials of Aakaar Medical

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days118136104114129166203
Inventory Days234366282274247202256
Days Payable28996562324924
Cash Conversion Cycle324403321326344320434
Working Capital Days1892381051029497199
ROCE %8%21%26%23%27%18%

Guidance history

How Aakaar Medical's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlanned——
Q4 FY26 call →20–40%FlatNone planned——
Q2 FY26 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

Others in Personal Products this season

  • Honasa Consumer (Q2 FY27)

    Revenue from operations for Q2 FY27: INR 731 Cr, a 35.9% YoY growth from INR 538 Cr in Q2 FY26. Key investor presentation takeaways from Honasa Consumer Ltd's Q

  • Emami (Q2 FY27)

    Q2FY27 Revenue from Operations:** ₹1,088 crore, up 36% year-on-year . Key investor presentation takeaways from Emami Ltd's Q2 FY27 investor presentation — and h

  • Dabur India (Q2 FY27)

    Consolidated Revenue: INR 3,563.1 crores in Q2 FY27, up 11.6% YoY (Page 27) . Key investor presentation takeaways from Dabur India Ltd's Q2 FY27 investor presen

  • JHS Svendgaard Laboratories (Q2 FY27)

    2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%. Key results statement takeaways from JHS Svendgaard Labor